Kedem Pharmaceuticals Introduces Their Sublingual Drug Delivery System
The company CEO Dr. Hasssan Salari will be on hand to discuss with the attendees the company's progress on X-Excite, the Company's lead therapeutic drug for erectile dysfunction. The Company's second lead therapeutic drug KDM-1102, which is a new sublingual formulation of Propanolol for cardiovascular diseases. The newest drug initiated into development of Gleevec(R). Gleevec(R) is an important anti-cancer drug for the treatment of several blood related cancers in children and adults.
Dr. Hassan Salari, Ph.D, C.E.O. expressed, "We were pleased to Welcome the Investors at the World Money Show forum and are excited to have a platform for review by the investment community. We welcome the opportunity to inform our shareholders in more detail about our goals to commercialize our sublingual drug delivery system.
If you are not attending the show you can visit our virtual E-Booth by registering at the link https://secure.moneyshow.com/Virtual_Show_Reg/TWMS/registration.asp?sid=TWMS12&scode=013104